Axsome to Acquire Homology Medicines for $1.1B
Ticker: QTTB · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1661998
| Field | Detail |
|---|---|
| Company | Homology Medicines, Inc. (QTTB) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, biotech
Related Tickers: AXSM
TL;DR
Axsome buying Homology for $1.1B cash, stockholders get $11/share.
AI Summary
Homology Medicines, Inc. announced on March 20, 2024, that it has entered into a definitive agreement to be acquired by Axsome Therapeutics, Inc. The transaction is valued at approximately $1.1 billion, with Homology stockholders expected to receive $11.00 per share in cash. This acquisition aims to expand Axsome's pipeline in neuroscience.
Why It Matters
This acquisition signifies a major consolidation in the gene therapy space, potentially impacting the future development and availability of treatments for rare genetic diseases.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approval and stockholder consent, which introduce uncertainty.
Key Numbers
- $1.1B — Acquisition Value (Total cash consideration for Homology Medicines)
- $11.00 — Price Per Share (Cash amount Homology stockholders will receive)
Key Players & Entities
- Homology Medicines, Inc. (company) — Company filing the 8-K and being acquired
- Axsome Therapeutics, Inc. (company) — Acquiring company
- $1.1 billion (dollar_amount) — Total value of the acquisition
- $11.00 per share (dollar_amount) — Cash price per share for Homology stockholders
- March 20, 2024 (date) — Date of the definitive agreement and report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the definitive agreement entered into by Homology Medicines, Inc. to be acquired by Axsome Therapeutics, Inc.
Who is acquiring Homology Medicines, Inc.?
Axsome Therapeutics, Inc. is acquiring Homology Medicines, Inc.
What is the total value of the acquisition?
The acquisition is valued at approximately $1.1 billion.
What will Homology Medicines stockholders receive per share?
Homology Medicines stockholders are expected to receive $11.00 per share in cash.
When was the definitive agreement announced?
The definitive agreement was announced on March 20, 2024.
Filing Stats: 1,820 words · 7 min read · ~6 pages · Grade level 20 · Accepted 2024-03-20 16:06:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FIXX The Nasdaq
Filing Documents
- d808597d8k.htm (8-K) — 34KB
- 0001193125-24-072689.txt ( ) — 153KB
- fixx-20240320.xsd (EX-101.SCH) — 3KB
- fixx-20240320_lab.xml (EX-101.LAB) — 17KB
- fixx-20240320_pre.xml (EX-101.PRE) — 11KB
- d808597d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HOMOLOGY MEDICINES, INC. Date: March 20, 2024 By: /s/ Paul Alloway, Ph.D. Paul Alloway, Ph.D. President, Chief Operating Officer and Secretary